Abstract
The aim of the study – to evaluate the effect of five-fold treatment of quercetin on thereproductive function of males in mice under conditions of experimental chronic kidneydisease (EChKD), namely: 1) the number of sperm (sperm concentration (million/ml)) andthe number of abnormal sperm (%)); and provided that such males are mated with intactfemales to assess: 2) the values of embryonic mortality before and after implantation;3) the number of live fetuses per female mouse.Materials and methods. The study was performed in two series of experiments on maleand female mice with EChKD, a model of which was created by immunizing animals withkidney homogenate.Quercetin (QUR, Sigma, USA) (50 mg / kg) was administered intraperitoneally oncedaily, five times according to the immunization schedule after the fourth immunization(the last, 3 weeks after the start of the experiment).The first series of experiments is devoted to the study of: the number of sperm (spermconcentration (million/ml)) and the number of abnormal forms of sperm.Fertile qualities of males were evaluated in the second series of experiments, afterreplanting them to intact females. Pre- and post-implantation embryonic mortality andthe number of living fetuses per female mouse have been investigated.Results. The treatment of QUR does not change the number of sperm, pre- and postimplantation embryonic mortality and the number of live newborns (pups) compared tosuch values in the control. The treatment of QUR in experimental chronic kidney disease leads to a decrease (1.60 times) in the number of abnormal sperm and the magnitude(1.37 times) of postimplantation mortality of embryos, as well as an increase (1.47 times)in the number of live newborns (pups).Conclusions. The treatment of Quercetin in experimental chronic kidney disease leads toa decrease in the number of abnormal sperm and postimplantation mortality of embryos,as well as an increase in the number of live fetuses per female.Quercetin may be recommended for the correction of spermatogenesis in chronic kidneydisease and to clarify new strategies for its treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
